Menu
Subscribe - Individual
Subscribe - Biotech Premium (Corporate)
Home
About Us
Subscribe
Subscribe Individual
Subscribe Biotech Premium (Corporate)
Premium Biotech Coverage
Current News
Special Features
Company Index
Index Table
Summit
19th Bioshares Biotech Summit
Summit History
Contact
Contact Us
Email Alerts
Categories
Categories
Actinogen (ACW)
Adalta (1AD)
Amplia Therapeutics (ATX)
Anteris Technologies (AVR)
Aroa Biosurgery (ARX)
Blinklab (BB1)
Blog
Botanix (BOT)
Chimeric Therapeutics (CHM)
Clever Culture Systems (CC5)
Clinuvel Pharmaceuticals (CUV)
Cogstate (CGS)
Dimerix (DXB)
EBR Systems (EBR)
Immuron (IMC)
Imugene (IMU)
Island Pharmaceuticals (ILA)
Neuren Pharmaceuticals (NEU)
Patrys (PAB)
Syntara (SNT) (previously Pharmaxis, PXS)
Uncategorized
September 4th, 2023
Robust Growth Expected to Continue for Clinuvel Pharmaceuticals
Read More
August 11th, 2023
2023 Bioshares Biotech Summit Coverage (Imugene)
Read More
August 11th, 2023
Pharmaxis - Meaningful Impact on Bone Marrow in Myelofibrosis Study
Read More
August 11th, 2023
Respiri - Targeting Cashflow Positive in 2024
Read More
August 11th, 2023
Dimerix in Partnering Discussions, Interim Results out March 2024
Read More
July 21st, 2023
Neuren Pharmaceuticals Moves to Worldwide License for Trofinetide and NNZ-2591 with Acadia
Read More
June 6th, 2023
Mixed Results from Pharmaxis' Scar Treatment Study
Read More
June 6th, 2023
EBR Systems Achieves Positive Results in Pivotal Study
Read More
May 19th, 2023
Immuron Receives FDA Clearance for Third US Study
Read More
May 19th, 2023
EBR Systems Pivotal Trial Results to be Announced this Week
Read More
May 19th, 2023
Dimerix to Raise $12 Million in Difficult Market
Read More
May 19th, 2023
Chimeric Therapeutics Opens $6.3 Million Capital Raise
Read More
May 19th, 2023
Anteris Technologies - Expands Programs to Mitral and Tricuspid Valve Repair
Read More
May 19th, 2023
Cogstate - Eli Lilly's Donanemab Confirms Benefit of Beta Amyloid Drugs for Alzheimer's
Read More
May 1st, 2023
Pharmaxis Phase II Trial Results Approaching
Read More
May 1st, 2023
Immuron – Sales Start to Rebound Strongly
Read More
April 6th, 2023
Imugene - Nine Clinical Programs to Advance in 2023
Read More
April 6th, 2023
Imricor Focuses on Dedicated iCMR Labs
Read More
April 6th, 2023
Chimeric Therapeutics - Viral Vector Manufacturing Achieved
Read More
April 6th, 2023
Anteris Technologies - Early Feasibility Study to Start Ahead of 1,000 Patient Pivotal Trial
Read More
Pages
1
2
3
4
5
6
7
8
9
